There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aratana (NASDAQ:PETX) and HTG Molecular Diagnostics (NASDAQ:HTGM) with bullish sentiments.
Aratana (PETX)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Aratana, with a price target of $10. The company’s shares closed on Friday at $4.62.
Ramakanth observed:
“We maintain our Buy rating of PETX and our 12-month price target of $10.00 per share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues through 2027 assuming a 10% discount rate and 3% terminal growth rate.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 5.7% and a 38.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aratana with a $8.50 average price target, implying an 84.0% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $7 price target.
.
See today’s analyst top recommended stocks >>
HTG Molecular Diagnostics (HTGM)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on HTG Molecular Diagnostics today and set a price target of $7. The company’s shares closed on Friday at $2.80.
Selvaraju commented:
“Our price target is derived from a market value of the firm at $192M excluding debt. This includes a discounted cash flow analysis based asset value at $202M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -4.8% and a 33.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on HTG Molecular Diagnostics is a Moderate Buy with an average price target of $7.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
